This is a working overview of reduced glutathione, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-19 and is reviewed periodically as new material appears.
Synthesis occurs in two ATP-dependent steps. The enzyme glutamate-cysteine ligase joins glutamate and cysteine to form gamma-glutamylcysteine, and glutathione synthetase adds glycine. The first step is rate-limiting and is influenced by cysteine availability and feedback inhibition by GSH. Breakdown involves gamma-glutamyl transferase and subsequent peptidases, which release constituent amino acids for reuse. Because turnover differs among tissues, measurements from blood, plasma, and tissues are not directly interchangeable. Research continues to clarify how compartment-specific pools are regulated in health and disease.
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine. It contains an unusual gamma-glutamyl bond between glutamate and cysteine, which resists cleavage by many peptidases. The reduced form, GSH, carries a thiol group on cysteine and is the dominant intracellular form in most cells. Its structure allows it to participate in redox reactions and to serve as a sulfur donor. The oxidized form, GSSG, consists of two GSH molecules joined by a disulfide bond.
In cells, glutathione helps maintain the reducing environment of the cytosol and supports enzymes that counteract reactive oxygen species. It acts as a cofactor for glutathione peroxidases, which reduce hydrogen peroxide and lipid peroxides, and for glutathione S-transferases, which conjugate electrophiles. The ratio of GSH to GSSG is often used as an indicator of oxidative stress, although the ratio can vary by compartment and cell type. Glutathione also stores cysteine, an amino acid that can be limiting for protein synthesis and antioxidant defense.
In living systems, glutathione occurs in millimolar concentrations in many cell types, while extracellular levels are generally much lower. The liver holds a substantial share of the body's total pool, and the molecule participates in reduction, detoxification, and amino acid transport. It also serves as a cofactor for enzymes such as glutathione peroxidase and glutathione S-transferase. Because the cysteine residue supplies a reactive thiol, glutathione can donate electrons and become oxidized. Cells regenerate reduced glutathione through glutathione reductase using NADPH.
Commercial glutathione is produced by microbial fermentation or chemical synthesis, then purified. Reduced and oxidized grades are offered separately, with purity specifications often exceeding 98 percent. The compound appears in foods such as fresh fruits, vegetables, and meats, although cooking and processing can lower amounts. Oral, topical, and inhaled forms are discussed in research and consumer contexts, but absorption and tissue delivery remain active areas of study. Regulatory status varies by country and intended use.
| Property | Value | Notes |
|---|---|---|
| Chemical formula | C10H17N3O6S | For reduced glutathione; the oxidized dimer has two sulfur atoms. |
| Molar mass | 307.32 g/mol | Calculated for the reduced form. |
| Appearance | White to off-white crystalline powder | Typical for solid reagent; solutions are usually colorless. |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar organic solvents. |
| Typical storage | -20 °C, desiccated, protected from light | Limits oxidation, moisture uptake, and degradation. |
Glutathione supports several cellular processes beyond direct antioxidant action. It serves as a cofactor for glutathione peroxidase and glutathione S-transferase enzymes, which reduce peroxides and conjugate electrophiles, respectively. The molecule also acts as a reservoir of cysteine, an amino acid that can limit protein synthesis and redox signaling. In human nutrition, oral glutathione is sold as a supplement, but how much intact glutathione reaches tissues after ingestion remains an active research question. Clinical claims about supplementation are not uniformly supported by controlled trials.
Glutathione is a small tripeptide built from glutamic acid, cysteine, and glycine. Its peptide bond between glutamate and cysteine involves the gamma-carboxyl group rather than the usual alpha-carboxyl group. This structure gives the molecule a reactive thiol on the cysteine residue. The reduced form, often abbreviated GSH, is the predominant intracellular species in many cell types. Because the thiol can donate electrons, glutathione participates in redox chemistry and in the conjugation of reactive molecules.
Glutathione reference materials are sensitive to oxygen, light, and elevated temperature. Solid material is typically stored desiccated at -20 °C or below, while solutions require tighter control because thiol oxidation proceeds faster in liquid form. Aqueous solutions are often prepared fresh, kept cold, and protected from air; some protocols add acid or chelating agents to slow metal-catalyzed oxidation. Repeated freeze-thaw cycles can accelerate degradation and should be avoided. Stability data vary by matrix, so laboratories usually verify performance with their own storage conditions.
Quality control for glutathione measurements includes calibration with authenticated standards, internal standards where available, blank correction, and spike recovery checks. Because glutathione can form during sample processing or degrade before analysis, pre-analytical handling is a major source of variability. Interlaboratory comparisons often show differences in reported values due to method-specific calibration and detection principles. Interpretive thresholds are context-dependent, and no single reference range applies across all tissues or matrices. Researchers generally report both reduced and oxidized forms, along with the method and sample handling details.
From the evident difference in the transport of solution and channel appearance, one can identify the separation effect for the determination of blood type. Noiphung et al. at 2014 followed up an approach in paper-based microfluidic blood typing using antibodies to cause red blood cells agglutination, and the group designed a new paper-based analytical device (PAD) for blood grouping that can be used for the synchronous performation of Rh and forward and reverse ABO blood grouping on the same device. Forward grouping is a blood typing procedure whereby patient red blood cells are mixed with Anti-A and Anti-B reagents. On the other hand, reverse typing is a blood typing procedure where patient serum is mixed with reagent A cells and reagent B cells. The results should be the opposite of forward typing. The designed device has two sides: forward (F) side, made of chromatography paper with three channels spotted with 1.5 mL Anti-A, Anti-B, and Anti-D antibody solutions each, and reverse (R) side, made with blood separation membrane and connected to A-type and B-type antibodies channels. The PAD is fabricated using a combination of wax dipping technologies to join Whatman chromatography paper and blood separation membrane. The device included three wax-printed channels for forward grouping, two of which were also applied for reverse grouping. While R-side was capable for whole blood sample analysis, Noiphung's group found that whole blood samples are too viscous to be directly applied on a paper-side of the device.
== Discovery == R7 was synthesized by the same researchers who were involved in the discovery of tropoflavin. A patent was filed for R7 in 2013 and was published in 2015. In 2016, it was reported to be in the preclinical stage of development. R7 was superseded by R13 because while R7 had a good drug profile in animals, it showed almost no conversion into tropoflavin in human liver microsomes. Tropoflavin, a naturally occurring flavonoid, was found to act as an agonist of the TrkB with nanomolar affinity (Kd ≈ 320 nM). Due to the presence of a vulnerable catechol group on its 2-phenyl-4H-chromene ring, tropoflavin is extensively conjugated via glucuronidation, sulfation, and methylation during first-pass metabolism in the liver and has a poor oral bioavailability of only 5% in mice upon oral administration. As such, tropoflavin itself is a poor candidate for clinical development as an oral medication. R7 is a derivative of tropoflavin with carbamate moieties on its hydroxyl groups, thereby protecting it from metabolism.
Vaginitis An infection of the vagina usually caused by a fungus. A woman with this condition may have itching or burning and may notice a discharge. Women who have diabetes may develop vaginitis more often than women who do not have diabetes. Vascular Relating to the body's blood vessels (arteries, veins, and capillaries). Vein Visceral neuropathy Vitrectomy Removing the gel from the center of the eyeball because it has blood and scar tissue in it that blocks sight. An eye surgeon replaces the clouded gel with a clear fluid. See also: Diabetic retinopathy. Vitreous humor The clear jelly (gel) that fills the center of the eye.
=== Studies indicating negligible effects === Studies in 2005 and earlier have concluded that DU ammunition has no measurable detrimental health effects. A 1999 literature review conducted by the Rand Corporation stated: "No evidence is documented in the literature of cancer or any other negative health effect related to the radiation received from exposure to depleted or natural uranium, whether inhaled or ingested, even at very high doses," and a RAND report authored by the U.S. Defense department undersecretary charged with evaluating DU hazards considered the debate to be more political than scientific. A 2001 oncology study concluded that "the present scientific consensus is that DU exposure to humans, in locations where DU ammunition was deployed, is very unlikely to give rise to cancer induction". Former NATO Secretary General Lord Robertson stated in 2001 that "the existing medical consensus is clear. The hazard from depleted uranium is both very limited, and limited to very specific circumstances". A 2002 study from the Australian defense ministry concluded that "there has been no established increase in mortality or morbidity in workers exposed to uranium in uranium processing industries...
Sources: en.wikipedia.org
== History == Cambrex was founded in 1979, when the Ennis Family acquired the castor oil and derivatives product lines from NL Industries. In 1987, CasChem was renamed Cambrex Corporation and became listed on NASDAQ. In 1990, Cambrex was listed on the NYSE. Cambrex entered the pharmaceutical market in 1994 with the acquisition of Nobel Pharma Chemistry business, now known as Cambrex Karlskoga AB and Cambrex Profarmaco. Through multiple acquisitions during the late 1990s, the firm entered the bioscience and the chiral enzymatic catalyst markets. Cambrex acquired two contract biopharmaceutical manufacturing facilities in 2001, to bulk manufacture biologics and pharmaceutical ingredients from clinical to commercial scales. In 2007, the firm decided to focus on its core competencies and sold the biologics business to Lonza Group. In 2008, Prosyntest (now Cambrex Tallinn) was acquired, and Steve Klosk was appointed CEO, while remaining President. To broaden their biocatalysis platform, Cambrex acquired IEP in 2010, now known as Cambrex IEP. In 2019, Cambrex acquired Avista Pharma Solutions for $252m to become a fully integrated CDMO. In late 2019, Cambrex was acquired by an affiliate of the Permira funds. In 2020, Cambrex completed a major expansion at its Edinburgh, UK facility known for solid form screening alongside a biopharmaceutical expansion at its Durham, NC facility. Thomas Loewald was appointed CEO of Cambrex in September 2020. In 2022, Cambrex acquired Q1 Scientific, based out of Waterford, Ireland.
The amount of alcohol on the breath can be measured, without requiring drawing blood, by blowing into a breathalyzer, resulting in a breath alcohol content (BrAC). The BrAC specifically correlates with the concentration of alcohol in arterial blood, satisfying the equation BACarterial = BrAC × 2251 ± 46. Its correlation with the standard BAC found by drawing venous blood is less strong. Jurisdictions vary in the statutory conversion factor from BrAC to BAC, from 2000 to 2400. Many factors may affect the accuracy of a breathalyzer test, but they are the most common method for measuring alcohol concentrations in most jurisdictions.
== See also == Alternative abiogenesis scenarios – Proposed alternative scenarios related to abiogenesis Autopoiesis – System capable of producing itself Formamide-based prebiotic chemistry – Scientific hypothesis that life originated from formamide precursors Proto-metabolism – Chemical reactions which turn into modern metabolism GADV-protein world hypothesis – Hypothetical stage of abiogenesis Genetic recombination – Shuffling of genetic material Shadow biosphere – Hypothetical biosphere of Earth Manganese metallic nodules – Mineral concretion found on the sea bottomPages displaying short descriptions of redirect targets Virus world hypothesis – Theory that viruses predate cellular life
=== Non-modifiable === Scandinavian or Northern European ancestry; Dupuytren's has been called the "Viking disease", though it is also widespread in some Mediterranean countries, e.g., Spain and Bosnia. Dupuytren's is uncommon among groups including Chinese and Africans. In June 2023 a study found that gene variants that were inherited from Neanderthals dramatically increased the odds of developing the condition Male sex; men are 80% more likely to develop the condition Age of 50 or over (5% to 15% of men in that group in the US); the likelihood of getting Dupuytren's disease increases with age A family history (60% to 70% of those affected have a genetic predisposition to Dupuytren's contracture)
MGM-16 is an opioid drug which is a synthetic derivative of mitragynine, a natural product derived from the Southeast Asian tree kratom. It is the 9-fluoro derivative of another semi-synthetic mitragynine derivative MGM-15, and is a comparatively potent opioid analgesic with approximately 240 times the potency of morphine. While several semi-synthetic derivatives of mitragynine such as 7-hydroxymitragynine and MGM-15 were widely sold in the United States as unscheduled designer drug alternatives to illicit opioids from around 2023–2026, it is unclear whether MGM-16 has appeared on the market to any significant extent. Nevertheless, on 2 July 2026, the DEA published a notice of intent to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16) under Schedule I of the Controlled Substances Act. As of August 5th, 2026 MGM-16 has been placed in Schedule I through an emergency temporary scheduling order, making unauthorized possession, manufacture, and distribution illegal under federal law.
Sources: en.wikipedia.org
GSH is the reduced form with a free thiol group, while GSSG is the oxidized disulfide-linked dimer. Most assays distinguish the two because their balance reflects redox conditions. The names are not interchangeable.
It is synthesized in the body from amino acids, so it is not classified as an essential dietary nutrient for most people. Dietary and supplemental forms are studied for their effects on tissue levels and health markers. Evidence varies by population and outcome.
The phrase highlights its high intracellular concentration and its role in several antioxidant and detoxification reactions. It is not the only antioxidant, and the term can oversimplify its functions. Scientific descriptions usually specify the pathway or enzyme involved.
It is a tripeptide rather than a full protein. Proteins generally contain many amino acids joined by alpha-peptide bonds, while glutathione has three residues and an unusual gamma-glutamyl linkage. That structure affects how enzymes recognize and break it down.